Drug Delivery Letters - Volume 14, Issue 3, 2024

Nanotechnology exhibits the advancement in the field of invention, by improving the potency of the formulation through the delivery of inventive solutions. To resolve several limitations related to conventional formulations, nanotechnology applications are increasing in the cosmetics and dermatological area. Cosmetic and dermatological preparations are considered a thriving branch of the body care arena and their usage has increased dramatically through the past years. Scientists are designing innovative delivery mechanisms and emerging innovations that are presently being utilized in the development of cosmetics. Inventive nanocarriers such as niosomes, liposomes, microemulsions, nanoemulsions, solid-lipid nanoparticles, nanospheres, and nanostructured (lipid) carriers have substituted the use of traditional drug delivery. These innovative nanocarriers have the convenience of better skin permeation, sustained and controlled drug delivery, precise location, higher stability, and greater incorporated capability. Since the usage of cosmetics has increased, the usual delivery system has been substituted by modern delivery approaches. The introduction of newer advancements and novel drug delivery systems make cosmetics and cosmeceuticals more popular with increased market share. This review article on nanotechnology employed in cosmetics and dermatology emphasizes the numerous innovative nanocarriers designed for cosmetic and dermatologic drug delivery, their negative and positive aspects, and their toxicity.

Background: Bioelectronic medicine is an emerging therapy that makes use of neural signals and the nervous system to help in the treatment of injuries and diseases. The nervous system consists of disciplined circuits that involve the communication of every major organ of the human body as all the organs of the human body are regulated and controlled by neural circuits. Objective: The objective of this review is to overview the current implementations of bioelectronic medicines within the human body. The main target is to heal the body without administering a wide array of exogenous drugs. On understanding these neural circuits at a molecular level, it could be possible to understand, manipulate, and modify the body's functioning with the help of electrical impulses to modify neural impulses. Methods: The literature related to bioelectronic medicines, and their applications was collected through different websites, academic research portals, and databases, sorted, and presented in this review. Results: Bioelectronic medicine is emerging as a cutting-edge area in healthcare, demonstrating its potential to transform the diagnosis and management of inflammation and related conditions. With established efficacy in a variety of disorders and marketed available treatments, it highlights an enormous shift toward individualized and specialized therapeutic approaches, providing promise for improved outcomes and a higher quality of life for patients worldwide. Conclusion: The study focuses on potential advances in bioelectronic medicine for alleviating inflammation and inflammatory disorders such as rheumatoid arthritis, diabetes, and spinal cord injury. Bioelectronic treatments provide innovative therapeutic options with the potential for considerable clinical effects.

Healthcare practitioners, patients, and consumers widely recognize the convenience associated with administering oral tablets. The emergence of orally disintegrating tablets (ODTs) represents a significant advancement in solid dosage forms, facilitating more convenient oral delivery while maintaining medication safety, effectiveness, and quality. The ODTs market is expected to experience continuous growth in the coming years despite the internal challenges faced by commercial manufacturers. This paper initiates a comprehensive discussion of the properties of ODTs, including palatability and taste, drug content, disintegration, mechanical strength, moisture content, safety, and efficacy. The formulation factors that affect each of these qualities are also discussed. Additionally, this review delves into the processes of the production of ODTs, encompassing the approaches and technologies from the mixing of active ingredients and recipients to the formation and packaging of ODTs. This review provides valuable insights into the advancement in ODTs technology, aiming to equip researchers with the knowledge necessary to improve quality and optimize efficiency, ultimately receiving high acceptance from patients or consumers.

The essential need for efficacious conveyance of therapeutics to specific tissues or cells, refinement of drug formulations, and the scalability of industrial production drives the present- day demand for enhanced drug delivery systems (DDS). Newly devised drugs often exhibit suboptimal biopharmaceutical properties, resulting in diminished patient adherence and adverse side effects. The paramount importance of site-specific drug delivery lies in its capacity to facilitate the targeted administration of diverse therapeutic agents, catering to both localized ailments and systemic treatments. Alongside targeted drug delivery strategies encompassing ligand-based targeting and stimuli-responsive systems, the advent of cutting-edge nanotechnologies such as nanoparticles, liposomes, and micelles has marked a paradigm shift. Additionally, personalized medicines have emerged as a consequential facet of drug delivery, emphasizing the customization of treatment approaches. Researchers have explored an excess of methodologies in the advancement of these formulation technologies, including stimuli-responsive drug delivery, 3D printing, gene delivery, and various other innovative approaches. This comprehensive review aims to provide a holistic understanding of the past, present, and future of drug delivery systems, offering insights into the transformative potential of emerging technologies.

Background: The SeDeM Expert Diagram System (SeDeM EDS) is an innovative formulation tool that provides an index of compressibility, which can be used to predict a powder's suitability for direct compression to produce acceptable tablets. Objective: This study investigated the application of this tool to evaluate multiple component powder formulation mixtures for direct compression of tablets. The SeDeM EDS was specifically used to characterize powder mixtures for fixed-dose combination (FDC) matrix-type tablets that contained multiple active ingredients, which has not been done previously with SeDeM EDS. Methods: The FDC matrix-type tablets contained diclofenac sodium and vitamins B1, B6 and B12 in fixed ratios, intended for the management of peripheral neuropathy. The parameters of the SeDeM EDS were determined for the multiple-component powder mixtures and the indices were calculated to predict direct compressibility. The FDC tablets were subsequently manufactured utilizing direct compression and subjected to pharmacotechnical test evaluations to measure the accuracy of the SeDeM EDS's predictions. Results: This study proved the versatility of the SeDeM EDS and its utility to adequately characterize FDC powder mixtures for matrix-type tablets manufactured by direct compression. Additionally, a new calculation was suggested to determine the percentage of corrective excipients required in the case when multiple incidence factor values are below the value of 5. Prediction of the correct quantity of corrective excipient to be added is important to obtain an acceptable direct compressible formulation. Conclusion: The results obtained confirmed that the SeDeM EDS correctly predicted the performance of all formulations.